|
|
|
| Presentation of HPV 16L1 Peptide-based HBcAg Virus-like Particle and Induction of Specific Antibody |
| SUN Wen-jia, YAO Yu-feng, YANG Xu, HUANG Wei-wei, LIU Cun-bao, LONG Qiong, CHU Xiao-jie, MA Yan-bing |
| Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming 650118, China |
|
|
|
Abstract Objective:To construct virus-like particles(VLPs) presenting QPLGVGISGHPLLNKLDDTE epitopes of HPV 16 L1, and detect its antigenic specificity. Methods:The reported effective HPV 16L1 epitopes was selected and used to be presented by HBcAg VLPs. The oligonucleotides encoding for the peptide was inserted into plasmid pHBcAg. The recombinant plasmid was transformed into DH5α cells, and the expression of the chimeric proteins was induced with IPTG and identified by SDS-PAGE. The proteins was purified with a procedure consists of ammonium sulfate precipitation and sucrose density gradient centrifugation, and the presence of VLPs was detected with HPLC of size-exclusion chromatography and electron microscopy. Western blot showed the specific bands of the expressed recombinant protein. Mice were immunized with the mixed VLPs, and the serum to identify HPV 16L1 protein was measured by Western blot. Results:The constructed recombinant plasmid was proven to be correct by restriction enzyme digestion and DNA sequencing. The recombinant protein was expressed efficiently, and presented as VLPs. Western blot showed that the antiserum of VLPs immunizied mice could be recogniazed specifically by the recombinant yeast expression of L1 protein. Conclusion:HBcAg VLPs could present HPV 16L1 epitope and the recombinant HBcAg/16L1 VLPs could stimulate special immune response.
|
|
Received: 22 September 2016
Published: 25 March 2017
|
|
|
|
|
| [1] Munoz N,Bosch F X,Castellsagué X,et al. Against which human papillomavirus types shall we vaceinate and serene the international perspective. Int J Cancer,2004,111(2):278-285.
[2] Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002. CA Cancer J Clin,2005,55(2):74-108.
[3] Richards K F,Bienkowska-Haba M,Dasgupta J,et al.Multiple heparin sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol,2013, 87(21):11426-11437.
[4] Buck C B,Day P M,Trus B L. The papillomavirus major capsid protein L1. Virology,2013,445(1):169-174.
[5] Lin L C,Lee T H,Chang C H,et al. Predictors of clinical deterioration during hospitalization following acute ischemic stroke. Eur Neurol, 2012, 67(3):186-192.
[6] Harro C D, Pan Y Y, Roden R B, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16L1 virus-like particle vaccine. J Natl Cancer Inst,2001,93(4):284-292.
[7] Cardone G,Moyer A L,Cheng N, et al.Maturation of the human papillomavirus 16 capsid. Mbio, 2014,5(4):1104-1114.
[8] De M C,Ferlay J,Franceschi S,et al. Global burden of cancers attributable to infections in 2008:a review and synthetic analysis. Lancet Oncol,2012,13(6):607-615.
[9] Roden R,Wu T C. How will HPV vaccines affect cervical cancer.. Nat Rev Cancer,2006,6(10):753-763.
[10] Fleury M J,Touzé A,Maurel M C,et al. Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci,2009,18(7):1425-1438.
[11] Christensen N D, Dillner J, Eklund C, et al. Surface conformational and linearepitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology,1996,223(1):174-184.
[12] Christensen N D, Cladel N M, Reed C A,et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology, 2001,291(2):324-334.
[13] Guan J, Bywaters S M, Brendle S A,et al. Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virologym, 2015,483:253-263.
[14] Lin Xia,Yangfei Xian,Daning Wang, et al. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Sci Rep, 2016,11(6):19042.
[15] Brooke B,Jhimli D,Michael K,et al.Crystal structures of four types of human papillomavirus L1 capsid proteins.The Journal of Biological Chemistry,2007,282(43):31803-31811.
[16] Ludmerer S W, Benincasa D, Mark G E. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol, 1996,70(7):4791-4794.
[17] Combita A L, Touzé A, Bousarghin L, et al. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol, 2002,76(13):6480-6486.
[18] Chen X S,Garcea R L,Goldberg I,et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell,2000,5(3):557-567.
[19] Lowe J,Panda D,Rose S,et al. Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. Virol J,2008,5(1):1.
[20] Schellenbacher C, Kwak K, Fink D,et al.Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol, 2013,133(12):2706-2713.
[21] Boxus M, Fochesato M, Miseur A, et al. Broad cross-protection is induced in preclinical models by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles. J Virol, 2016,90(14):6314-6325. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
